
GH Research PLC
GHRSHealthcare|Biotechnology|Ireland
$26.67
-0.74 (-2.72%)
Tangible Book
$4.24
Earnings Power
$4.29
Analyst Estimates
annual
{
"date": [
"202612",
"202712",
"202812",
"202912",
"203012"
],
"revenue_estimate": [
null,
null,
0.92,
53.69,
283.87
],
"ebit_estimate": [
-96.66,
-147.46,
-174.55,
-179.13,
-50.52
],
"ebitda_estimate": [
-82.95,
-120,
-134.3,
-195.8,
-84.25
],
"net_income_estimate": [
-91.77,
-138.41,
-170.61,
-176.55,
-47.3
],
"per_share_eps_estimate": [
-1.4,
-2,
-2.25,
-2.13,
-0.74
],
"eps_nri_estimate": [
-1.4,
-2,
-2.25,
-2.13,
-0.98
],
"dividend_estimate": [
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
4.85,
4.66,
5.45,
5.66,
5.19
],
"pretax_income_estimate": [
-93.84,
-144.04,
-170.61,
-174.88,
-47.3
],
"operating_cash_flow_per_share_estimate": [
-0.88,
-1.52,
-1.3,
-2.31,
-1.38
],
"roa_estimate": [
null,
null,
null,
null,
null
],
"roe_estimate": [
-26,
-35.6,
-31.4,
-44.7,
-11.2
],
"gross_margin_estimate": [
null,
null,
null,
61.67,
61.67
],
"operating_cash_flow_estimate": [
-54.59,
-94.29,
-80.64,
-143.3,
-85.61
],
"pettm_estimate": [
0,
0,
0,
0,
0
],
"long_term_growth_rate_mean": -41.86,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": -41.86,
"future_eps_nri_estimate_growth": -41.86,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -43.19,
"future_ebitda_estimate_growth": -31.45,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -52.19,
"future_pretax_income_estimate_growth": -52.46,
"future_book_value_per_share_estimate_growth": 5.43,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": -16.36,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": -26.63
}
quarterly
{
"date": [
"202606",
"202609",
"202612",
"202703",
"202706",
"202709",
"202712"
],
"revenue_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"ebit_estimate": [
-21.04,
-24.65,
-30.18,
null,
null,
null,
null
],
"ebitda_estimate": [
-19.8,
-20.8,
-23.8,
null,
null,
null,
null
],
"net_income_estimate": [
-20.25,
-23.75,
-29.49,
null,
null,
null,
null
],
"per_share_eps_estimate": [
-0.32,
-0.36,
-0.42,
-0.35,
-0.39,
-0.43,
-0.47
],
"eps_nri_estimate": [
-0.32,
-0.36,
-0.42,
-0.35,
-0.39,
-0.43,
-0.47
],
"dividend_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"book_value_per_share_estimate": [
5.41,
5,
4.68,
null,
null,
null,
null
],
"pretax_income_estimate": [
-20.25,
-23.75,
-29.36,
null,
null,
null,
null
],
"operating_cash_flow_per_share_estimate": [
-0.18,
-0.22,
-0.29,
null,
null,
null,
null
],
"roa_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"roe_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"gross_margin_estimate": [
null,
null,
null,
null,
null,
null,
null
],
"operating_cash_flow_estimate": [
-11.17,
-13.65,
-17.99,
null,
null,
null,
null
],
"pettm_estimate": [
0,
0,
0,
0,
null,
null,
null
],
"long_term_growth_rate_mean": -41.86,
"long_term_revenue_growth_rate_mean": "0.00",
"future_per_share_eps_estimate_growth": -41.86,
"future_eps_nri_estimate_growth": -41.86,
"future_revenue_estimate_growth": null,
"future_ebit_estimate_growth": -43.19,
"future_ebitda_estimate_growth": -31.45,
"future_dividend_estimate_growth": null,
"future_net_income_estimate_growth": -52.19,
"future_pretax_income_estimate_growth": -52.46,
"future_book_value_per_share_estimate_growth": 5.43,
"future_roa_estimate_growth": null,
"future_roe_estimate_growth": -16.36,
"future_gross_margin_estimate_growth": null,
"future_operating_cash_flow_per_share_estimate_growth": -26.63
}